Literature DB >> 9202057

Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin.

D A Waltz1, L R Natkin, R M Fujita, Y Wei, H A Chapman.   

Abstract

The urokinase receptor (uPAR) coordinates plasmin-mediated cell-surface proteolysis and promotes cellular adhesion via a binding site for vitronectin on uPAR. Because vitronectin also binds plasminogen activator inhibitor type 1 (PAI-1), and plasmin cleavage of vitronectin reduces PAI-1 binding, we explored the effects of plasmin and PAI-1 on the interaction between uPAR and vitronectin. PAI-1 blocked cellular binding of and adhesion to vitronectin by over 80% (IC50 approximately 5 nM), promoted detachment of uPAR-bearing cells from vitronectin, and increased cellular migration on vitronectin. Limited cleavage of vitronectin by plasmin also abolished cellular binding and adhesion and induced cellular detachment. A series of peptides surrounding a plasmin cleavage site (arginine 361) near the carboxy-terminal end of vitronectin were synthesized. Two peptides spanning res 364-380 blocked binding of uPAR to vitronectin (IC50 approximately 8-25 microM) identifying this region as an important site of uPAR-vitronectin interaction. These data illuminate a complex regulatory scheme for uPAR-dependent cellular adhesion to vitronectin: Active urokinase promotes adhesion and also subsequent detachment through activation of plasmin or complex formation with PAI-1. Excess PAI-1 may also promote migration by blocking cellular adhesion and/or promoting detachment, possibly accounting in part for the strong correlation between PAI-1 expression and tumor cell metastasis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9202057      PMCID: PMC508165          DOI: 10.1172/JCI119521

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  61 in total

1.  Novel purification of vitronectin from human plasma by heparin affinity chromatography.

Authors:  T Yatohgo; M Izumi; H Kashiwagi; M Hayashi
Journal:  Cell Struct Funct       Date:  1988-08       Impact factor: 2.212

2.  Vitronectin (serum spreading factor): its localisation in normal and fibrotic tissue.

Authors:  J T Reilly; J R Nash
Journal:  J Clin Pathol       Date:  1988-12       Impact factor: 3.411

Review 3.  The directed migration of eukaryotic cells.

Authors:  S J Singer; A Kupfer
Journal:  Annu Rev Cell Biol       Date:  1986

Review 4.  Cell-associated plasminogen activation: regulation and physiological functions.

Authors:  O Saksela; D B Rifkin
Journal:  Annu Rev Cell Biol       Date:  1988

Review 5.  Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness.

Authors:  F Blasi
Journal:  Bioessays       Date:  1993-02       Impact factor: 4.345

6.  Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer.

Authors:  F Jänicke; M Schmitt; L Pache; K Ulm; N Harbeck; H Höfler; H Graeff
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

7.  Cytokines induce urokinase-dependent adhesion of human myeloid cells. A regulatory role for plasminogen activator inhibitors.

Authors:  D A Waltz; L Z Sailor; H A Chapman
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

8.  High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.

Authors:  J Grøndahl-Hansen; I J Christensen; C Rosenquist; N Brünner; H T Mouridsen; K Danø; M Blichert-Toft
Journal:  Cancer Res       Date:  1993-06-01       Impact factor: 12.701

9.  Prevention of metastasis by inhibition of the urokinase receptor.

Authors:  C W Crowley; R L Cohen; B K Lucas; G Liu; M A Shuman; A D Levinson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

10.  Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?

Authors:  G Deng; S A Curriden; S Wang; S Rosenberg; D J Loskutoff
Journal:  J Cell Biol       Date:  1996-09       Impact factor: 10.539

View more
  60 in total

1.  Urokinase-receptor/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo.

Authors:  G van der Pluijm; B Sijmons; H Vloedgraven; C van der Bent; J W Drijfhout; J Verheijen; P Quax; M Karperien; S Papapoulos; C Löwik
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

2.  Vitronectin accumulates in the interstitium but minimally impacts fibrogenesis in experimental chronic kidney disease.

Authors:  Jesús M López-Guisa; Allen C Rassa; Xiaohe Cai; Sarah J Collins; Allison A Eddy
Journal:  Am J Physiol Renal Physiol       Date:  2011-01-26

3.  Directional migration and transcriptional analysis of oligodendrocyte precursors subjected to stimulation of electrical signal.

Authors:  Yongchao Li; Xinkun Wang; Li Yao
Journal:  Am J Physiol Cell Physiol       Date:  2015-08-12       Impact factor: 4.249

4.  Vitronectin-binding PAI-1 protects against the development of cardiac fibrosis through interaction with fibroblasts.

Authors:  Jianyong Zhong; Hai-Chun Yang; Valentina Kon; Agnes B Fogo; Daniel A Lawrence; Ji Ma
Journal:  Lab Invest       Date:  2014-03-31       Impact factor: 5.662

5.  Metals affect the structure and activity of human plasminogen activator inhibitor-1. II. Binding affinity and conformational changes.

Authors:  Lawrence C Thompson; Sumit Goswami; Cynthia B Peterson
Journal:  Protein Sci       Date:  2011-02       Impact factor: 6.725

Review 6.  Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycle.

Authors:  Lea M Beaulieu; Brandi R Whitley; Theodore F Wiesner; Sophie M Rehault; Diane Palmieri; Abdel G Elkahloun; Frank C Church
Journal:  Bioessays       Date:  2007-10       Impact factor: 4.345

7.  Dual role for plasminogen activator inhibitor type 1 as soluble and as matricellular regulator of epithelial alveolar cell wound healing.

Authors:  François Maquerlot; Stephane Galiacy; Michel Malo; Christophe Guignabert; Daniel A Lawrence; Maria-Pia d'Ortho; Georgia Barlovatz-Meimon
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

8.  Plasminogen activator inhibitor-1 removal using dextran sulphate columns. Evidence of PAI-1 homeostasis.

Authors:  Vincent M G Maher; Yuri Kitano; Clare Neuwirth; Graham J Davies; Attilio Maseri; Gilbert R Thompson; Felicita Andreotti
Journal:  J Thromb Thrombolysis       Date:  2008-07-30       Impact factor: 2.300

9.  Urokinase type plasminogen activator receptor expression in colorectal neoplasms.

Authors:  S Suzuki; Y Hayashi; Y Wang; T Nakamura; Y Morita; K Kawasaki; K Ohta; N Aoyama; S R Kim; H Itoh; Y Kuroda; W F Doe
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

10.  Involvement of hypoxia-inducing factor-1alpha-dependent plasminogen activator inhibitor-1 up-regulation in Cyr61/CCN1-induced gastric cancer cell invasion.

Authors:  Ming-Tsan Lin; I-Hsin Kuo; Cheng-Chi Chang; Chia-Yu Chu; Hsing-Yu Chen; Been-Ren Lin; Munisamy Sureshbabu; Hou-Jung Shih; Min-Liang Kuo
Journal:  J Biol Chem       Date:  2008-04-01       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.